Integra LifeSciences launches EGR system in the U.S.

Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the launch of the Integra™ Endoscopic Gastroc Release (EGR) System in the United States. Integra's EGR System is a disposable device with a unique articulating blade that allows selective cutting of soft tissues. It is intended for use in the surgical treatment for posterior heel cord, or equinus, contracture.

"We are very pleased to offer this exciting new addition to our lower extremity product line. The retractable blade technology is an integrated system that allows surgeons to control the position of the blade and limit the uncertainty in determining exactly which tissues to cut," said Pete Ligotti, Vice President of Sales and Marketing for Integra Extremity Reconstruction. "We also plan to expand this product line with the release of additional sizes."

Equinus contracture is a condition that limits ankle motion, frequently due to contraction or tightness of the calf muscle. Surgical treatment involves recession of selected tissues of the calf muscle (composed of the gastrocnemius and soleus muscle complex). Traditionally performed as an open procedure, the recession of the gastrocnemius aponeurosis can be performed endoscopically through a small incision.  This is a minimally invasive, less traumatic procedure that produces a smaller and less apparent scar.

Gastrocnemius recession is being used increasingly as a component in the surgical treatment of posterior tibial tendon dysfunction (PTTD), diabetic forefoot ulcers, symptomatic acquired flatfoot, and hallux valgus.

The EGR System will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.

SOURCE Integra LifeSciences Holdings Corp.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)